<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - SODIUM VALPROATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>SODIUM VALPROATE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#effectOnLaboratoryTests" data-toggle="tab">Effect on laboratory tests</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">All forms of epilepsy</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 600 mg daily in 1&#8211;2 divided doses, then increased in steps of 150&#8211;300 mg every 3 days; maintenance 1&#8211;2 g daily, alternatively maintenance 20&#8211;30 mg/kg daily; maximum 2.5 g per day.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                Initially 10&#8211;15 mg/kg daily in 1&#8211;2 divided doses (max. per dose 600 mg); maintenance 25&#8211;30 mg/kg daily in 2 divided doses, doses up to 60 mg/kg daily in 2 divided doses may be used in infantile spasms; monitor clinical chemistry and haematological parameters if dose exceeds 40 mg/kg daily.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 600 mg daily in 1&#8211;2 divided doses, increased in steps of 150&#8211;300 mg every 3 days; maintenance 1&#8211;2 g daily in 2 divided doses; maximum 2.5 g per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Initiation of valproate treatment</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10 mg/kg, (Usually 400&#8211;800 mg), followed by (by intravenous infusion or by intravenous injection) up to 2.5 g daily in 2&#8211;4 divided doses, alternatively (by continuous intravenous infusion) up to 2.5 g daily; (by intravenous injection or by intravenous infusion or by continuous intravenous infusion) usual dose 1&#8211;2 g daily, alternatively (by intravenous injection or by intravenous infusion or by continuous intravenous infusion) usual dose 20&#8211;30 mg/kg daily, intravenous injection to be administered over 3&#8211;5 minutes.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Continuation of valproate treatment</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intravenous infusion or by continuous intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                If switching from oral therapy to intravenous therapy give current oral daily dose, give over 3&#8211;5 minutes by intravenous injection or in 2&#8211;4 divided doses by intravenous infusion.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Migraine prophylaxis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 200 mg twice daily, then increased if necessary to 1.2&#8211;1.5 g daily in divided doses.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Valproate is associated with the highest risk of major and minor congenital malformations (in particular neural tube defects), and long-term neurodevelopmental effects. Valproate should not be used during pregnancy or in women of child-bearing potential unless there is no safer alternative and only after a careful discussion of the risks. </p><p>If valproate is to be used during pregnancy, the lowest effective dose should be prescribed in divided doses or as modified-release tablets to avoid peaks in plasma-valproate concentrations; doses greater than 1&#8239;g daily are associated with an increased risk of teratogenicity.</p><p>Avoid use in the treatment of epilepsy and bipolar disorder unless there is no safer alternative and only after a careful discussion of the risks&#8212;effective contraception advised in women of child-bearing potential.</p><p>Avoid use for the prophylaxis of migraine [unlicensed]&#8212;exclude pregnancy before treatment and ensure effective contraception is used during treatment.</p><p>Neonatal bleeding (related to hypofibrinaemia) reported.</p><p>Neonatal hepatotoxicity also reported.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid if possible&#8212;hepatotoxicity and hepatic failure may occasionally occur (usually in first 6 months).</p><p>Avoid in active liver disease.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce dose.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Family history of severe hepatic dysfunction</li>
            <li>known mitochondrial disorders (higher rate of acute liver failure and liver-related deaths)</li>
            <li>personal or family history of severe hepatic dysfunction</li>
            <li>porphyria</li>
            <li>suspected mitochondrial disorders (higher rate of acute liver failure and liver-related deaths)</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Aggression, anaemia, confusion, convulsion, deafness, diarrhoea, extrapyramidal disorders, gastric irritation, haemorrhage, headache, hyponatraemia, memory impairment, menstrual disturbance, nausea, nystagmus, somnolence, stupor, thrombocytopenia, transient hair loss (regrowth may be curly), tremor, weight gain,
              </p>
              <p>
                <strong>uncommon:</strong> Angioedema, ataxia, coma, encephalopathy, increased alertness, lethargy, leucopenia, pancytopenia, paraesthesia, peripheral oedema, rash, reduced bone mineral density, syndrome of inappropriate secretion of antidiuretic hormone, vasculitis,
              </p>
              <p>
                <strong>rare:</strong> Behavioural disturbance, blood disorders, bone marrow failure, dementia in adults, drowsiness, drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, enuresis, Fanconi&#8217;s syndrome, hallucinations, hearing loss, hyperactivity, hyperammonaemia, hypothyroidism, learning disorders, male infertility, myelodysplastic syndrome, polycystic ovaries, Stevens-Johnson syndrome, systemic lupus erythematosus, toxic epidermal necrolysis,
              </p>
              <p>
                <strong>veryRare:</strong> Acne, gynaecomastia, hepatic dysfunction, hirsutism, increase in bleeding time, pancreatitis,
              </p>
              <p>
                <strong>notKnown:</strong> Hypersensitivity reactions, suicidal ideation,
              </p>
        
        
            <section class="advice">
                <h3>Hepatic dysfunction</h3>
              <p>Withdraw treatment immediately if persistent vomiting and abdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or loss of seizure control.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous injection</i>, may be diluted in Glucose 5% <i>or</i> Sodium Chloride 0.9% and given over 3&#8211;5 minutes.</p><p>For <i>intravenous infusion</i>, dilute injection solution with Glucose 5% <i>or</i> Sodium Chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">rectal</ph> use in children</h3>
              <p>For <i>rectal administration</i>, sodium valproate oral solution may be given rectally and retained for 15 minutes (may require dilution with water to prevent rapid expulsion).</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Epilim</i>
            <tm tmtype="reg"/>, <i>Episenta</i>
            <tm tmtype="reg"/>), give continuously <i>or</i> intermittently <i>in</i> Glucose 5% <i>or</i> Sodium Chloride 0.9%. Reconstitute <i>Epilim</i>
            <tm tmtype="reg"/> with solvent provided then dilute with infusion fluid.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Blood or hepatic disorders</h3>
              <p>Patients or their carers should be told how to recognise signs and symptoms of blood or liver disorders and advised to seek immediate medical attention if symptoms develop.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Pancreatitis</h3>
              <p>Patients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek immediate medical attention if symptoms such as abdominal pain, nausea, or vomiting develop; discontinue if pancreatitis is diagnosed.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Sodium valproate for preventing seizures</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/sodium-valproate-for-preventing-seizures">www.medicinesforchildren.org.uk/sodium-valproate-for-preventing-seizures</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Systemic lupus erythematosus
          </li>
        </ul>
        <ul>
          <li>
            <p>Liver dysfunction (including fatal hepatic failure) has occurred in association with valproate (especially in children under 3 years and in those with metabolic or degenerative disorders, organic brain disease or severe seizure disorders associated with mental retardation) usually in first 6 months and usually involving multiple antiepileptic therapy. Raised liver enzymes during valproate treatment are usually transient but patients should be reassessed clinically and liver function (including prothrombin time) monitored until return to normal&#8212;discontinue if abnormally prolonged prothrombin time (particularly in association with other relevant abnormalities).</p>
          </li>
          <li>
            <p>Consider vitamin D supplementation in patients that are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Valproate is associated with teratogenic risks and should not be used in women of child-bearing potential unless there is no safer alternative&#8212;this should be fully considered and discussed before prescribing for women of child-bearing age.</p><p>Effective contraception advised in women of child-bearing potential.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <p>Plasma-valproate concentrations are not a useful index of efficacy, therefore routine monitoring is unhelpful.</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor liver function before therapy and during first 6 months especially in patients most at risk.</p><p>Measure full blood count and ensure no undue potential for bleeding before starting and before surgery.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In adults</h3>
              <p>Not licensed for migraine prophylaxis.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
                <h3>Switching between formulations</h3>
              <p>Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.</p><p>Patients being treated for epilepsy may need to be maintained on a specific manufacturer&#8217;s branded or generic oral sodium valproate product.</p>
            </section>
      </section>





      <section class="tab-pane" id="effectOnLaboratoryTests">
        <h2>Effect on laboratory tests</h2>

            <section class="effectOnLaboratoryTests">
              <p>False-positive urine tests for ketones.</p>
            </section>
      </section>




      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of SODIUM VALPROATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            suppository,
            oral suspension,
            oral solution,

            <div id="PHP77460"><a href="../medicinalForm/PHP77460.html" data-target="#PHP77460" data-action="load">Tablet</a></div>
            <div id="PHP77472"><a href="../medicinalForm/PHP77472.html" data-target="#PHP77472" data-action="load">Modified-release tablet</a></div>
            <div id="PHP77467"><a href="../medicinalForm/PHP77467.html" data-target="#PHP77467" data-action="load">Gastro-resistant tablet</a></div>
            <div id="PHP77482"><a href="../medicinalForm/PHP77482.html" data-target="#PHP77482" data-action="load">Modified-release capsule</a></div>
            <div id="PHP77496"><a href="../medicinalForm/PHP77496.html" data-target="#PHP77496" data-action="load">Modified-release granules</a></div>
            <div id="PHP77491"><a href="../medicinalForm/PHP77491.html" data-target="#PHP77491" data-action="load">Oral solution</a></div>
            <div id="PHP76148"><a href="../medicinalForm/PHP76148.html" data-target="#PHP76148" data-action="load">Solution for injection</a></div>
            <div id="PHP77476"><a href="../medicinalForm/PHP77476.html" data-target="#PHP77476" data-action="load">Powder and solvent for solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
